Sangamo Therapeutics, Inc. (SGMO)

Market Cap	78.75M -49.9%
Revenue (ttm)	39.55M -31.6%
Net Income	-122.93M
EPS	-0.44
Shares Out	414.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,127,799
Open	0.2500
Previous Close	0.2550
Day's Range	0.1402 - 0.2547
52-Week Range	0.1402 - 0.8400
Beta	1.50
Analysts	Strong Buy
Price Target	7.00 (+3,582.27%)
Earnings Date	May 11, 2026

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO
• Website: https://www.sangamo.com

Financial Performance

In 2025, Sangamo Therapeutics's revenue was $39.55 million, a decrease of -31.57% compared to the previous year's $57.80 million. Losses were -$122.93 million, 25.5% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SGMO stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 3,582.27% from the latest price.

Price Target

$7.0

(3,582.27% upside)

Analyst Consensus: Strong Buy